A randomized study comparing mitomycin C, mitomycin C plus epirubicin and mitomycin C plus interferon-alpha-2 in the intravesical prophylaxis of superficial bladder tumour recurrences

1997 ◽  
Vol 64 (4) ◽  
pp. 419-421
Author(s):  
V. Serretta ◽  
V. Falletta ◽  
P. Vasile ◽  
S. Pomara ◽  
B. Piazza
Keyword(s):  
Statistical Analysis ◽  
Mitomycin C ◽  
Interferon Alpha ◽  
Randomized Study ◽  
Bladder Tumour ◽  
Intravesical Treatment ◽  
Superficial Bladder Tumour ◽  
Bladder Tumours

– After TUR of superficial bladder tumours (G1-G3, Ta-T1), 121 patients were randomized in three groups of intravesical treatment: mitomycin C alone, mitomycin C plus epirubicin, mitomycin C plus interferon-alpha-2. At a mean follow-up of 53 months, 64 patients (52.8%) showed a recurrence. A trend (p < 0.02) in favour of the combination of mitomycin C and epirubicin was evident. The higher efficacy of this association was particularly evident when patients with primary tumours were excluded from the statistical analysis.

Treatment of superficial bladder tumors with alpha 2b Interferon and Epirubicin

1992 ◽  
Vol 59 (1_suppl) ◽  
pp. 127-129
Author(s):  
T. Zenico ◽  
M. Zoli ◽  
F. Fabbri ◽  
C. Camporesi ◽  
G. Maltoni
Keyword(s):  
Endoscopic Treatment ◽  
Slow Growth ◽  
Bladder Tumour ◽  
Tumour Recurrence ◽  
Bladder Tumors ◽  
Endoscopic Control ◽  
Intravesical Treatment ◽  
Superficial Bladder Tumour ◽  
One Year ◽  
Bladder Tumours

The relapse of superficial bladder tumours can be prevented, after endoscopic treatment, by intravesical chemo and immunoprophylaxis. In the first 6 months of 1991, 14 patients (13 males, 1 female, average age 58.3) were treated endoscopically for superficial bladder tumours, which had been detected on average 3.5 years earlier. Intravesical treatment was with 50 mg Epirubicin and, after 3 hours, alpha-2b Interferon once a week for 8 weeks. The patients had a hematological and cystoscopic control every 3 months for one year. A decrease in tumour recurrence was noted at the first endoscopic control, then only slow growth of superficial bladder tumour recurrence was observed.

Tumori superficiali della vescica: Presentazione di uno studio comparativo tra la sola resezione endoscopica e I'uso di BCG, epirubicina o mitomicina C adiuvanti

1997 ◽  
Vol 64 (1_suppl) ◽  
pp. 14-17
Author(s):  
R. Iantorno ◽  
E. Ballone ◽  
M. Nicolai ◽  
M. Passamonti ◽  
G. Mastroprimiano ◽  
...  
Keyword(s):  
Clinical Study ◽  
Adjuvant Therapy ◽  
Mitomycin C ◽  
Endoscopic Resection ◽  
Bladder Tumour ◽  
Bacillus Calmette Guerin ◽  
Tumour Stage ◽  
Retrospective Clinical Study ◽  
Superficial Bladder Tumour

A retrospective clinical study was carried out to compare results obtained with just endoscopic resection and with adjuvant use of the Bacillus Calmette-Guérin (BCG), epirubicin and mitomycin C after TURB in patients with superficial bladder tumour (stage pTa/1 grade 1-3). At an average follow-up of 44 months, a decrease in the percentage of recurrences was noted in all the adjuvant therapy groups compared to that in the group subjected to TURB only. The risk of recurrence for the BCG group was 0.427, for the epirubicin group 0.609 and for the mitomycin C group 0.668. There was progression of the disease in: 5.6% of the TURB, 9.1% of the BCG, 5% epirubicin and 3.6% mitomycin C, for a total of 26 patients (7.3%). Twenty-four cystectomies were performed and 2 patients died due to progression of the disease. At 44 months average follow-up, 353 (98.6%) patients are alive and 329 (93.2%) still have their own bladder.

scholarly journals Intracameral Bevacizumab Versus Sub-Tenon’s Mitomycin C as Adjuncts to Trabeculectomy: 3-Year Results of a Prospective Randomized Study

2021 ◽  
Vol 10 (10) ◽  
pp. 2054
Author(s):  
Gerasimos Kopsinis ◽  
Dimitrios Tsoukanas ◽  
Dimitra Kopsini ◽  
Theodoros Filippopoulos
Keyword(s):  
Mitomycin C ◽  
Primary Outcome ◽  
Randomized Study ◽  
Primary Outcome Measure ◽  
Complication Rates ◽  
Filtration Surgery ◽  
Significant Difference ◽  
Exfoliative Glaucoma

Conjunctival wound healing determines success after filtration surgery and the quest for better antifibrotic agents remains active. This study compares intracameral bevacizumab to sub-Tenon’s mitomycin C (MMC) in trabeculectomy. Primary open-angle or exfoliative glaucoma patients were randomized to either bevacizumab (n = 50 eyes) or MMC (n = 50 eyes). The primary outcome measure was complete success, defined as Intraocular Pressure (IOP) > 5 mmHg and ≤ 21 mmHg with a minimum 20% reduction from baseline without medications. Average IOP and glaucoma medications decreased significantly in both groups at all follow-up points compared to baseline (p < 0.001), without significant difference between groups at 3 years (IOP: bevacizumab group from 29 ± 9.4 to 15 ± 3.4 mmHg, MMC group from 28.3 ± 8.7 to 15.4 ± 3.8 mmHg, p = 0.60; Medications: bevacizumab group from 3.5 ± 0.9 to 0.5 ± 1, MMC group from 3.6 ± 0.7 to 0.6 ± 1.1, p = 0.70). Complete success, although similar between groups at 3 years (66% vs. 64%), was significantly higher for bevacizumab at months 6 and 12 (96% vs. 82%, p = 0.03; 88% vs. 72%, p = 0.04, respectively) with fewer patients requiring medications at months 6, 9 and 12 (4% vs. 18%, p = 0.03; 6% vs. 20%, p = 0.04; 8% vs. 24%, p = 0.03, respectively). Complication rates were similar between groups. In conclusion, intracameral bevacizumab appears to provide similar long-term efficacy and safety results as sub-Tenon’s MMC after trabeculectomy.

Intraoperative Application of Mitomycin C in the Surgical Treatment of Pterygium

1998 ◽  
Vol 8 (3) ◽  
pp. 153-156 ◽  
Author(s):  
A. Demirok ◽  
S. Simsek ◽  
A. Çinal ◽  
T. Yasar
Keyword(s):  
Statistical Analysis ◽  
Surgical Treatment ◽  
Side Effects ◽  
Mitomycin C ◽  
Surgical Excision ◽  
Control Group ◽  
Exact Test ◽  
Pterygium Surgery ◽  
Group 1

Purpose To investigate the effectiveness of intraoperative mitomycin C in pterygium surgery. Methods The effectiveness of intraoperatively administered mitomycin C and the occurrence of postoperative complications were evaluated in 17 patients with two recurrences of pterygium. The authors employed the “bare-sclera technique” and placed a sterile sponge soaked in a 0.02% mitomycin C solution intraoperatively in the episcleral space for 3 minutes. The control group (15 patients) underwent only surgical excision. Patients were followed for 21 to 30 months. Results The pterygium recurred in one (5.9%) of the 17 patients in group 1 and in six (40%) of the 15 controls. Statistical analysis using Fisher's exact test showed a significant (p=0.027) reduction of recurrences of pterygium in the group treated intraoperatively with mitomycin C. No serious complications or side effects arose during the follow-up period. Conclusions Mitomycin C administered intraoperatively can be considered an effective treatment to improve the success rate after surgical excision.

Immunotherapeutic treatment of superficial bladder tumours using BCG. Preliminary results

1998 ◽  
Vol 65 (1) ◽  
pp. 65-68
Author(s):  
C. Nisticò ◽  
F. Abate ◽  
G. Amuso ◽  
S. Bartolotta ◽  
F. Caizzone ◽  
...  
Keyword(s):  
Mitomycin C ◽  
Toxic Effects ◽  
Bacillus Calmette Guerin ◽  
Preliminary Results ◽  
First Results ◽  
Low Toxic ◽  
Bladder Tumours

Chemotherapy using drugs such as mitomycin C or epirubicin is well known in the treatment of superficial bladder tumours, while use of BCG (Bacillus Calmette-Guérin) in the same pathology is more recent. The first authors to test the BCG were Co? and Feldman, then Zbar fixed the criteria for correct use in the treatment of superficial bladder tumours. First results encouraged the preparation of a drug that could reduce the toxic effects without reducing demonstrated efficacy. Our experience started recently with the introduction onto the market of the Connaught strain, which we prefer to use due to its low toxic effects. We wish to evaluate the tolerability of BCG in a short follow-up period (six months) with cystoscopic controls.

scholarly journals Comparison of Subconjunctival Mitomycin C and 5-Fluorouracil Injection for Needle Revision of Early Failed Trabeculectomy Blebs

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Wei Liu ◽  
Jianrong Wang ◽  
Miaomiao Zhang ◽  
Yuan Tao ◽  
Yan Sun
Keyword(s):  
Mitomycin C ◽  
Randomized Study ◽  
Prospective Randomized Study ◽  
Rank Test ◽  
Complication Rates ◽  
Success Rates ◽  
Log Rank Test ◽  
The Mean ◽  
Needle Revision

Background. To compare the efficacy of needle revision with 5-fluorouracil (5-FU) and mitomycin C (MMC) on dysfunctional filtration blebs shortly after trabeculectomy.Methods. It is a prospective randomized study comparing needle revision augmented with MMC or 5-FU for failed trabeculectomy blebs.Results. To date 71 patients (75 eyes) have been enrolled, 40 eyes in the MMC group and 35 in the 5-FU group. 68 patients (72 eyes) have completed 12-month follow-up, 38 eyes in the MMC group and 34 in the 5-FU group. The mean IOP before and that after needle revision in the MMC group were26.5±4.3 mmHg and11.3±3.4 mmHg, respectively (P<0.05), and in the 5-FU group were27.1±3.8 mmHg and10.9±3.4 mmHg, respectively (P<0.05). At 12-month follow-up, complete success rates were 57.5% for MMC group and 34.3% for 5-FU group (P=0.042; log-rank test) and 75% and 60% (P=0.145; log-rank test), respectively, for the qualified success. Complication rates between the two groups were not statistically different (P>0.05).Conclusions. Needle revision and subconjunctival MMC injection were more effective than needling and subconjunctival 5-FU injection for early dysfunctional filtration blebs after trabeculectomies.

COMPLICATIONS OF BCG INTRAVESICAL TREATMENT FOR SUPERFICIAL BLADDER TUMOURS - 21 YEARS' FOLLOW-UP

2006 ◽  
Vol 5 (2) ◽  
pp. 189
Author(s):  
D.A. Georgescu ◽  
P. Geavlete ◽  
I. Arabagiu ◽  
D. Soroiu
Keyword(s):  
Intravesical Treatment ◽  
Bladder Tumours

scholarly journals Cold en bloc excision (CEBE) of bladder tumours using Zedd excision scissors: a prospective, pilot, safety and feasibility study

2020 ◽  
Vol 12 ◽  
pp. 175628722097223
Author(s):  
Hameed BMZ ◽  
Padmaraj Hegde ◽  
Milap Shah ◽  
Bhavan Prasad Rai ◽  
Joseph Thomas ◽  
...  
Keyword(s):  
Bladder Tumour ◽  
Posterior Wall ◽  
Bladder Perforation ◽  
Detrusor Muscle ◽  
En Bloc ◽  
En Bloc Excision ◽  
The Mean ◽  
Bloc Excision ◽  
Bladder Tumours

Background: Transurethral resection of bladder tumour (TURBT) is the traditional technique of choice for endoscopically suspected bladder tumours. Cold En Bloc Excision (CEBE) using novel Zedd scissors is proposed for endoscopic treatment of patients with non-muscle invasive bladder cancer (NMIBC). The aim of this study was to evaluate feasibility and safety of CEBE of bladder tumours using Zedd scissors. Methods: A pilot prospective study of patients who underwent a CEBE of suspicious bladder tumours using Zedd scissors was conducted. A total of 23 patients underwent CEBE for suspected bladder tumours using Zedd scissors. New and recurrent tumours <3 cm were included in the study. The outcome measures were the presence of detrusor muscle (DM) and obturator nerve reflex (ONR), bladder perforation rates, specimen cautery artefacts, recurrence rates and complication rates. The mean age was 64 years ± 10.41 (range: 49–83 years). The median follow up was 4 months (range 1–9 months). The mean tumour size was 1.8 cm ± 0.40 (range: 0.8–2.6 cm). Tumours were located in the lateral wall ( n = 11), dome ( n = 2), posterior wall ( n = 6), trigone ( n = 2), anterior wall ( n = 4) and the junction of lateral and posterior wall ( n = 4). Results: There was no ONR or bladder perforation and none of the patients had any complications. DM was present in 21 patients (91%). There was no tumour identified at the circumferential margins. There was no cautery artefact reported in any case. No patients had a recurrence at first follow up cystoscopy and two patients had out of field recurrence at subsequent cystoscopies. Conclusion: CEBE with Zedd scissors is a promising en bloc excision technique for bladder tumour. It is a safe and feasible for excision of tumours less than 3 cm. The early oncological outcomes are comparable with existing en bloc resection techniques (ERBT) for NMIBC.

Bladder tumours in the young: Our experience

1994 ◽  
Vol 61 (2) ◽  
pp. 95-97
Author(s):  
A. Spasari ◽  
A. Scalfari ◽  
A.G. Ventrice ◽  
F. Falvo ◽  
D. Pirritano ◽  
...  
Keyword(s):  
Urinary Diversion ◽  
Bladder Tumour ◽  
Invasive Disease ◽  
Continent Urinary Diversion ◽  
The Mean ◽  
Bladder Tumours

In the last ten years (1983–1993) we treated 18 patients, 17 men and 1 woman, less than 40 years old, with bladder tumour: nine were 15 to 30 years old. The mean follow-up is 40 months. All the patients are living. Of the 18, 2 (more than 30 years old) have had resectable recurrences, in one (27 years old), cystectomy and continent urinary diversion was performed for invasive disease. We think that all patients regardless of age, should be treated as aggressively as necessary on the basis of the stage and grade of the tumour.

scholarly journals Occupation and Bladder Tumor: Result of the incident cases

2016 ◽  
Vol 9 (3) ◽  
Author(s):  
Muhammad Muzammil Tahir ◽  
Khizar Hayat ◽  
Kamran Hassan Bhatti ◽  
Sajjad Husain
Keyword(s):  
Diagnostic Tool ◽  
Bladder Tumor ◽  
Economic Condition ◽  
Bladder Tumour ◽  
Office Workers ◽  
Superficial Bladder Tumour ◽  
Set Up ◽  
Incident Cases ◽  
Dye Industry

Bladder tumour is a devastating condition demand a lot of consultation and follow up. In patients suffering from superficial bladder tumour recurrence rate after five years follow up is 15-20%. The occupation most commonly concerned with bladder tumour are farmers. persons dealing with pesticide, dye industry, transport and office workers. We conducted the study to see the occupational involvement in our set up. We found the farmers 43.2% are most commonly involved in bladder tumour. The uncontrolled use of pesticides, illiteracy, poor economic condition and non-availability of basic diagnostic tool at gross root level are the main cause in its late diagnosis and treatment.

Sign in / Sign up

Export Citation Format

Share Document